Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded by StockNews.com

StockNews.com downgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a hold rating to a sell rating in a research note published on Monday.

A number of other analysts have also commented on AGIO. Cantor Fitzgerald reissued an overweight rating on shares of Agios Pharmaceuticals in a research report on Monday, June 17th. JPMorgan Chase & Co. reissued a neutral rating and set a $46.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, June 13th. Royal Bank of Canada raised their price objective on Agios Pharmaceuticals from $53.00 to $55.00 and gave the company an outperform rating in a report on Friday, August 2nd. Finally, The Goldman Sachs Group upped their target price on Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a neutral rating in a report on Tuesday, June 4th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, Agios Pharmaceuticals has a consensus rating of Hold and an average target price of $51.33.

Agios Pharmaceuticals Trading Up 2.9 %

AGIO stock opened at $43.79 on Monday. The stock has a market cap of $2.49 billion, a PE ratio of -6.93 and a beta of 0.79. The stock has a 50-day moving average price of $45.00 and a two-hundred day moving average price of $35.06. Agios Pharmaceuticals has a 1 year low of $19.80 and a 1 year high of $50.35.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The firm had revenue of $8.60 million for the quarter, compared to the consensus estimate of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 44.84% and a negative net margin of 1,165.69%. The firm’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.51) earnings per share. On average, analysts forecast that Agios Pharmaceuticals will post -2.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Agios Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Federated Hermes Inc. grew its holdings in Agios Pharmaceuticals by 9.0% during the second quarter. Federated Hermes Inc. now owns 13,394 shares of the biopharmaceutical company’s stock worth $578,000 after purchasing an additional 1,108 shares during the period. American Century Companies Inc. raised its stake in Agios Pharmaceuticals by 17.2% in the second quarter. American Century Companies Inc. now owns 94,486 shares of the biopharmaceutical company’s stock valued at $4,074,000 after buying an additional 13,870 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Agios Pharmaceuticals in the second quarter valued at approximately $494,000. Quest Partners LLC bought a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth approximately $40,000. Finally, Acadian Asset Management LLC acquired a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth approximately $37,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.